08:08 AM EDT, 03/11/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Sunday that a phase 3 study of lebrikizumab, an investigational treatment for eczema, showed "significant" efficacy in improving skin clearance and in itch relief for people with skin of color.

About 68% of the study's patients experienced at least 75% improvement in disease extent and severity, Eli Lilly ( LLY ) said, adding that about 46% experienced 90% improvement.

Meanwhile, 55% of the patients showed clinically meaningful itch relief, while 39% achieved clear or almost clear skin, the company said.

The population was composed of 80% African-American patients, 14% Asian and 6% American Indian or Alaska Native, according to the company.

No serious adverse events were reported, according to Eli Lilly ( LLY ).

Price: 750.9, Change: -11.24, Percent Change: -1.47